Multimodal Imaging Market

Multimodal Imaging Market Outlook (2025 to 2035)

The global multimodal imaging market is expected to reach USD 4,678 million by 2035, up from USD 2,976 million in 2024. The industry is projected to expand at a Compounded Annual Growth Rate (CAGR) of 4.2% during the forecast period. Need for non-invasive diagnosis has also promoted huge levels of investment in research and development to enable continuous advancements in multimodal imaging.

The application of artificial intelligence (AI) and machine learning (ML) to image analysis has increased diagnostic rates, reduced scan times, and made workflow more efficient in hospitals and imaging centers.

Over the span of next ten years, the industry is poised to grow 1.5X with incremental dollar opportunity of USD 1,577.8 million in the (2025 to 2035). This indicates a promising outlook for the multimodal imaging market, with considerable potential for expansion and investment.

Metric	Value
Industry Value (2025E)	USD 3,100 Million
Industry Size (2035F)	USD 4,678 Million
CAGR (2025 to 2035)	4.2%

The introduction of hybrid imaging modalities, i.e., PET/CT, PET/MR, and SPECT/CT, has revolutionized clinical diagnosis by enabling more anatomical and functional images. These machines facilitate the advanced characterization of disease, diagnosis at earlier stages, and treatment assessment and therefore have become indispensable diagnostic machines in contemporary health care.

What are the key factors driving growth in the multimodal imaging market?

Some drivers are propelling the multimodal imaging market. Increasing rates of chronic diseases of cancer, cardiovascular disease, and neurodegenerative diseases are fueling demand for precise imaging. Improvements in AI and machine learning technology have enhanced image analysis and diagnostic efficiency.

Government policies and medical imaging device research grants are also propelling innovation. The demand for early detection of disease and the integration of multimodal imaging in personalized medicine is also driving adoption. The shift towards minimally invasive diagnosis procedures is also driving healthcare centers to invest in advanced hybrid imaging equipment.

What are the primary market restraints affecting the multimodal imaging market?

Even with phenomenal growth, there are numerous challenges that are curbing the market from still higher growth. Exorbitant prices for multimodal imaging technology, especially PET/MR and SPECT/CT, pose an economic hurdle to most healthcare providers. Restrictive payment practices against cutting-edge imaging technology in developing nations limit access further.

Highly restricted regulatory measures and lengthy time for clearance of new imaging technology limit market entry. Under-trained radiologists and technicians who are proficient to read multimodal images is a central limitation. Patient safety and radiation exposure issues continue to drive purchasing and thus inhibit adoption in some geographies and applications.

What are the emerging market trends in multimodal imaging, and how are they influencing innovation and competitive dynamics in the industry?

Some of the foremost market trends in the multimodal imaging market include greater usage of AI and deep learning in imaging diagnosis to improve accuracy and efficiency of diagnoses. Increased demand for low-radiation imaging products like PET/MR scanners for pediatric and re-scan cases is on the rise.

Hybrid imaging also finds increasing application in drug development, with such modalities used by drug corporations to create biomarkers and quantitate treatment. Cloud computing-based imaging and teleradiology are also finding favor, supporting remote diagnosis as well as speedy image transfer across doctors. Industry player's business combinations in the imaging technology arena are also spearheading innovation as well as industry growth.

What are the key opportunities and challenges driving growth in the multimodal imaging market?

Among the industry challenges are over-capital investment in equipment, regulatory hurdles, and poorly trained personnel, which have impeded growth in developing economies. Standardized imaging protocols and improved reimbursement agreements are an issue. The market does have some opportunities, such as AI-based imaging solutions, which improve diagnostic accuracy.

Growth in multimodal imaging for precision medicine holds the promise of more targeted therapies. Besides that, growth prospects in the market are also emerging in the form of expanded healthcare infrastructure spending in Asia-Pacific and additional research partnerships in oncology and neuroimaging. Enhancements in radiotracers and molecular imaging also provide growth opportunities driven by innovation.

Which global regions lead the multimodal imaging market and what drives their success?

Geographically, the multimodal imaging market is divided into Western Europe, East Asia, North America, and South Asia & Pacific. Of these, the largest market share is commanded by North America based on its well-developed healthcare infrastructure, greater use of high-end imaging devices, and more investment in R&D in medicine. In particular, the United States is a leader in AI-based imaging software and hybrid imaging solutions, offering better clinical results.

Western Europe is next, with Germany, France, and the UK dominating multimodal imaging adoption. Regional market growth has been triggered by access to well-equipped healthcare centers, growing government initiatives towards research, and firm industry-academia interactions.

Growth is occurring in the Asia-Pacific nations, including China, Japan, and India, at a rapid pace through higher expenditure on healthcare, a rise in early disease detection awareness, and evolving medical imaging facilities. Governments there are spending hugely on healthcare technology, thus bringing about multimodal imaging adoption once again. South Asia & Pacific is also growing due to enhanced medical tourism as well as increasing diagnostic imaging facilities in developing economies.

What key technology segments significantly drive expansion in the multimodal imaging market?

The multimodal imaging market is segmented based on technology, including :

PET/CT Systems:

Multimodal imaging systems that combine positron emission tomography (PET) and computed tomography (CT) in the field of providing precise anatomical as well as metabolic imaging. PET/CT systems are being widely used in cardiology, oncology, and neurology and were found to possess better diagnostic capability and remain two of the most widely used multimodal imaging systems clinically.

SPECT/CT Systems:

With the inclusion of single-photon emission computed tomography (SPECT) and CT scanning, the scanners now have the ability to provide improved functional imaging. The systems are used predominantly for cardiovascular and bone disease assessment but also used for oncology and neuroimaging, where function and anatomy co-registration provides best diagnosis and treatment planning.

The most rapidly expanding subsegment, PET/MR systems integrate PET functional imaging features with the increased soft tissue contrast of magnetic resonance imaging (MRI). PET/MR is most valuable in oncology and neurology, with reduced radiation doses and improved and more informative imaging data, fueling its market penetration.

OCT/Fundus Imaging Systems:

These optical imaging instruments are of utmost significance in ophthalmology, and these imaging modalities have great application in the diagnosis of retinal disease, glaucoma, and diabetic retinopathy. OCT/fundus imaging's new high-resolution imaging technology extends conventional eye examination as well as sophisticated ophthalmic examination, thus quintessentially driving market demand for this application market.

Others:

This segment includes the new hybrid imaging modalities combining modalities like ultrasound, optical imaging, and novel AI-based solutions. These solutions are driving real-time imaging and expanding applications in the cardiovascular, oncology, and neurosurgery segments. New innovations of these solutions are also expanding the multimodal imaging market space.

Other modalities include PET/MR systems that are rapidly becoming the fastest-growing subsegment of the multimodal imaging market. This is because there are a number of key factors. PET/MR systems combine the functional metabolic imaging potential of PET with the high-contrast soft tissue resolution of MRI and hence are suitable to differentiate brain tumors, neurodegenerative disease, and certain cancers where tissue discrimination accurately is required.

The expansion is driven by technology, with PET/MR imaging being used by neurology and oncology more and more in applications as the gold standard for disease diagnosis of Alzheimer's, Parkinson's disease, and epilepsy, and monitoring of tumors for brain, liver, and prostate.

In addition, increased applications of PET/MR for clinical and drug trial research-drug development of pharmaceuticals and discovering biomarkers-also drive the market growth. Overall, the multimodal imaging market is poised to witness strong growth in the next decade with technology development, AI implementation, and R&D expenditure growth in the healthcare sector, led by North America and Europe but the Asia-Pacific region growing exponential.

Shifts in the Multimodal Imaging Market from (2020 to 2024) and Future Trends (2025 to 2035)

The multimodal imaging industry expanded at a superrapid pace in the years 2020 to 2024 with improvement in medical imaging technology, increased prevalence of chronic disease, and growing research utilization for neurosciences and oncology.

Utilization of imaging with more than one modality, i.e., PET-CT, PET-MRI, and SPECT-CT, has enhanced yield in diagnosis and patient prognosis as well. Grants from the government and government grants to research work in imaging have also been the key driver for growth in market penetration.

Along the way to 2025 to 2035, the market will see the transition to AI-supported image analysis, cheaper and lighter multimodal imaging devices, and greater emphasis on personalized medicine. Noninvasive and precise diagnosis will be demand-driven, especially in cardiology, neurology, and oncology. To this is added the regulation shift in a direction to ease the entry of new imaging technology without compromising patient safety standards.

Comparative Market Analysis: Key Trends and Future Projections

Market Shift	2020 to 2024
Regulatory Landscape	Stringent regulations on imaging device approvals; compliance with FDA, EMA, and other global regulatory bodies.
Technological Advancements	Expansion of PET-CT, PET-MRI, and SPECT-CT applications; improvements in hybrid imaging technology.
Industry-Specific Demand	High demand from oncology, neurology, and cardiology for accurate disease diagnosis.
Production & Supply Chain	Dominance of established players in imaging device manufacturing; supply chain disruptions due to global crises.
Market Growth Drivers	Growing burden of chronic diseases, increasing R&D investment in medical imaging, and government support.

Market Shift	2025 to 2035
Regulatory Landscape	More adaptive regulatory frameworks to accommodate AI-integrated imaging and personalized diagnostic solutions.
Technological Advancements	Growth of AI-driven image processing, enhanced machine learning for real-time diagnostics, and development of miniaturized imaging systems.
Industry-Specific Demand	Rising adoption in personalized medicine, drug discovery, and precision healthcare, with increased applications in mental health diagnostics.
Production & Supply Chain	Decentralization of manufacturing, increased reliance on AI-driven supply chain optimization, and local production to reduce dependencies.
Market Growth Drivers	AI-driven innovations, increasing access to multimodal imaging in emerging economies, and the shift towards early disease detection and preventive diagnostics.

The multimodal imaging industry will see transformative growth over the decade due to AI penetration, accurate diagnostic imaging, and increasing significance of personalized medicine.

Technological advancement will improve accuracy and affordability of imaging, tilting the market more towards greener, cheaper, and patient-centric imaging techniques. Regulator bodies will have to ensure future imaging technology meets stringent efficacy and safety standards, driving continued growth in this high-speed industry.

Country-wise Outlook

United States

Multimodal imaging in the US economy is expanding extremely rapidly as a result of the gigantic burden of chronic ailments such as cancer, cardiovascular disease, and neurological disease. The health care system in the United States is strong and in overall equipment for state-of-the-art multimodal imaging modalities such as PET-CT, PET-MRI, and SPECT-CT exists in humongous quantities.

Huge R&D costs, particularly in AI-imaging technology, result in better patient outcomes and better diagnosis. Also, FDA clearance of new imaging devices and hybrid products and technologies is driving market adoption. Medical professionals, with wider use of machine learning and AI in image interpretation, are increasing the rate of diagnosis and accuracy and thereby generating market growth prospects in the forecast period.

Germany

Multimodal imaging is gaining momentum in Germany with its well-established health infrastructure, solid research foundation, and increasing demand for precise diagnostic equipment. Germany, with one of the longest traditions in medical imaging technology, is now trying to find new fields of application for hybrid imaging technology in oncology, neurology, and cardiology.

Apart from top-notch educational facilities with enhanced imaging equipment, the positive government initiatives towards AI-based healthcare solutions are driving the market trend. Digitization of the healthcare industry, telemedicine, and remote diagnosis creating demand for multimodal imaging technology is one of the driving factors in another direction in the case of Germany.

With increased numbers of elderly people on the population growth curve and an increasing emphasis on the diagnosis of diseases at early stages, the market will keep growing steadily over the next few years.

China

The multimodal imaging market in China is evolving at a rapid rate due to enhanced healthcare infrastructure, rising spending on health, and government-supported upgradation of diagnosis imaging policies. Growing incidence of chronic diseases, especially neurological and oncological diseases, is fueling demand for high-end imaging technology.

China is adopting artificial intelligence and machine learning for medical imaging entirely to enhance efficiency and efficacy of diagnosis. China has indigenous R&D and production on imaging system technology based on minimal dependence on imports. Diagnostic institutes, centers, and hospitals will be impacted by the boom of adopting multimodal imaging since it is cutting through the urban as well as the rural market.

Japan

Multimodal imaging in Japan is increasing due to its immense interest in technological upgradation and medical research. With extremely high proportion of geriatric population and rapidly rising rates of chronic disease incidence, high accuracy imaging modalities such as PET-MRI and SPECT-CT become invaluable.

As a global leader in artificial intelligence imaging diagnosis, Japan has spent heavily in deep learning and automation of approaches to enhance accuracy using imaging. Additionally, health care provider's collaborations with the government and technology firms are driving application and innovation using hybrid imaging technology.

Precision care and precision medicine and targeted care also are prevalent multimodal imaging use in such a way and driving the market ahead, extremely highly positioning Japan in its world number one position again in our current day global age of imaging.

Country-Wise Insights

Country	Attributes
U.S. Market Value (2025E)	USD 949.1 Mn
Germany (CAGR%)	4.0%
China Market Value (2025E)	USD 496.3 Mn
Japan (CAGR%)	3.4%

Category-Wise Market Outlook

Multimodal Imaging Market Outlook - Growth Drivers and Fastest Growing Segments

By Technology - PET/MR Systems Drive Growth

PET/MR Systems are the fastest-growing segment of the multimodal imaging market because of increased imaging capability, with functional imaging by PET supplemented by high soft-tissue contrast of MRI. It finds significant application in oncology and neurology with precise tumor localization and brain imaging of utmost concern.

Growth is driven by the incidence of neurodegenerative disorders such as Alzheimer's and Parkinson's, which are more prevalent in nature, and due to the requirement for cancer diagnosis at an early stage. Advances in technology in the form of higher resolution and accuracy of diagnosis also drive PET/MR systems growth.

By Product - Software Segment Drives the Growth

The software industry is driving multimodal imaging by bringing artificial intelligence (AI) and machine learning technology into image reconstruction, analysis, and automated workflow. Cloud terminals for imaging and PACS and AI-driven software products are being implemented in hospitals and diagnostic centers to accelerate accurate diagnosis. Apart from this, multimodal image interpretation is enabled using AI algorithms as well as detection of the disease with reduced diagnostic error.

By Application - Oncology Driving Demand

Oncology is the most rapidly expanding use of multimodal imaging systems. Increasing global oncologic burden is a key driver for PET/CT and PET/MR imaging solutions demand. The technologies provide higher metabolic and structural resolution enabling uniform tumor staging, treatment, and monitoring of treatment response.

Increasing interest in targeted therapy and personalized medicine also drives increasing demand for high-resolution oncology imaging modalities. Government-funded early cancer-screening programs and supportive reimbursement policies in mature economies are also driving adoption.

By End User - Diagnostic Imaging Centers Growing Fastest

Diagnostic imaging centers are growing fastest among multimodal imaging equipment end users. Outpatient imaging procedures have been witnessing increased investment in advanced imaging systems in imaging centers with cost benefits and convenience.

Increasing demand for detecting the disease at an earlier stage and minimally invasive diagnostic imaging also is propelling higher adoption rates. Technologies that optimize the productivity of imaging and minimize scan time make multimodal imaging increasingly cost-effectively available to freestanding imaging centers, further expanding the market.

The multimodal imaging business is developing very rapidly because of technology application, increasing disease burden, and demand for efficient and reliable diagnostic products. PET/MR systems, artificial intelligence imaging software, oncology, and diagnostic imaging centers are revolutionizing and will shape the future of medical imaging.

Competitive Analysis

Competitive Outlook Report: Multimodal Imaging Market

Multimodal imaging firm is moving very rapidly in medical disease diagnosis by PET-CT, PET-MRI, SPECT-CT, and Optical Imaging to diagnose disease more effectively and for research purposes. Two or more modalities enhance the detection rate at a high rate with a good view of anatomical as well as functional changes.

There is trend alignment that is blind and re-forming the market. Emerging technologies like AI-driven imaging, hybrid imaging platforms, and real-time data integration are re-making image quality, diagnostic capability, and productivity. There is consolidation of the market via acquisition and merger of companies in an effort to make their imaging infrastructure and broaden their global reach.

Compliance is highest with FDA and EMA regulatory compliances too because, after the device has been cleared through fixed market access programs and cleared, safety and efficacy requirements are highest and also the companies are forced to walk the very fine line of global needs.

Key players in the market include Bruker Corp., Spectrum Dynamics Medical Inc., Nipro Corp., PerkinElmer Inc., Shanghai Unitsed Imaging Healthcare Co. Ltd., Engineering GmbH, Koninklijke Philips NV, Mediso Ltd., Canon Inc., Carl Zeiss AG, and MILabs BV.

Company Name	Estimated Market Share (%)
Top 5 players	~60 - 65%
Tier II players	~15 - 20%
Others	~15 - 25%

Key Company Offerings and Activities

Company Name	Key Offerings/Activities
Siemens AG	Leader in PET-CT, PET-MRI; AI-driven imaging solutions.
General Electric Co. (GE Healthcare)	Strong in SPECT-CT, PET-CT; focus on AI and cloud-based imaging.
Koninklijke Philips NV & Mediso Ltd.	MRI-PET leader; specializes in radiation dose reduction.
Canon Inc.	Focus on ultrasound-CT, cardiovascular imaging.
Bruker Corp.	Leader in preclinical imaging, specializing in PET-MR, optical imaging.
Carl Zeiss AG	Optical and ophthalmic imaging leader, specializing in high-precision medical imaging.
MILabs BV	Expertise in preclinical PET-SPECT-CT imaging.
PerkinElmer Inc.	Specializes in molecular imaging, optical and PET imaging.

Key Company Insights

Siemens AG

Siemens AG dominates PET-CT and PET-MRI imaging, constantly improving diagnostic yield and workflow productivity. The company incorporates AI-based imaging algorithms to enhance disease detection and radiology workflow productivity. Siemens is heavily investing in building its portfolio of hybrid imaging solutions, especially in oncology and neurology, to facilitate early diagnosis and treatment planning.

General Electric Co. (GE Healthcare)

GE Healthcare is a worldwide industry leader in the provision of PET-CT and SPECT-CT imaging using innovative multimodal systems, providing diagnostic value to medicine from all clinical specialties. GE Healthcare is investing heavily in cloud-based image platforms, thus ensuring integration becomes seamless with the information and seamless remote access of image information. GE Healthcare is associated with hospitals along with research centers so as to turn innovations in products like accurate diagnosis and treatment that centers on patients.

Koninklijke Philips NV & Mediso Ltd.

Philips and Mediso are at the forefront of low-dose multimodal imaging with focus on MRI-PET hybrid technology that delivers top-quality images at minimal radiation exposure to the patient. They are at the front in neurological imaging applications where there is high accuracy for detecting neurological diseases such as neurodegenerative diseases and brain tumours. Philips and Mediso also see opportunities for them to expand their market share in the worldwide market of AI-based imaging and patient-oriented imaging solutions.

Multimodal Imaging Market is growing strongly with demands for AI diagnosis, hybrid imaging technology, and personalized medicine. Market leaders Siemens, GE Healthcare, and Philips are driving the market, with opportunity to compete from preclinical and specialty imaging technology start-ups. Technology advancements, approvals, and partnerships will propel steadily increasing rates of diagnosis accuracy and medical image fusion to propel future market growth.

Fact.MR has provided detailed information about the price points of key manufacturers of multimodal imaging market positioned across regions, sales growth, production capacity, and speculative technological expansion, in the recently published report.

Segmentation of Multimodal Imaging Market Research

• By Technology :

  • PET/CT Systems
  • SPECT/CT Systems
  • PET/MR Systems
  • OCT/Fundus Imaging Systems
  • Others

• By Product :

  • Equipment
  • Reagents
  • Software

• By Application :

  • Brain & Neurology
  • Cardiology
  • Oncology
  • Ophthalmology
  • Other Applications

• By End User :

  • Hospitals
  • Diagnostic Imaging Centers
  • Others

• By Region :

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • East Asia
  • South Asia & Pacific
  • Middle East & Africa